RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.040
0.00 (0.00%)
At close: Nov 5, 2024, 4:00 PM
1.000
-0.040 (-3.85%)
After-hours: Nov 5, 2024, 4:31 PM EST
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RenovoRx, Inc.
Country | United States |
Founded | 2012 |
IPO Date | Aug 26, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Shaun Bagai |
Contact Details
Address: 4546 El Camino Real, Suite B1 Los Altos, California 94022 United States | |
Phone | 650 284 4433 |
Website | renovorx.com |
Stock Details
Ticker Symbol | RNXT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $9.00 |
CIK Code | 0001574094 |
CUSIP Number | 75989R107 |
ISIN Number | US75989R1077 |
Employer ID | 27-1448452 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Shaun R. Bagai | Chief Executive Officer, Secretary and Director |
Dr. Ramtin Agah M.D. | Founder, Chairman of Board and Chief Medical Officer |
Ronald B. Kocak CPA, CGMA | Vice President, Controller and Principal Accounting Officer |
Leesa Gentry | Chief Clinical Officer |
Ryan Witt | Senior Vice President and Head of Corporate Strategy and Partnerships |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 25, 2024 | 8-K | Current Report |
Aug 16, 2024 | 8-K | Current Report |
Aug 13, 2024 | 10-Q | Quarterly Report |
Jun 7, 2024 | 8-K | Current Report |
May 10, 2024 | EFFECT | Notice of Effectiveness |
May 10, 2024 | EFFECT | Notice of Effectiveness |
May 10, 2024 | 10-Q | Quarterly Report |
May 10, 2024 | 424B3 | Prospectus |
May 10, 2024 | 424B3 | Prospectus |
May 3, 2024 | 8-K | Current Report |